Recent advances in immunotherapy for cancer have led to the licensing of new biotherapeutics for prostate cancer and melanoma. However, there is a general recognition that immunotherapy alone will not be sufficient to deliver benefit to all patients.

New combinations of immunotherapy and drug treatments have led slowly to the concept that some commonly used drugs may synergize with immunotherapy. There is increasing in vitro and in vivo evidence to support the emerging concept of chemotherapy/immunotherapy combinations for cancer.

The Cancer Vaccine Institute’s 1st International Symposium on Immunotherapy will be held at The Royal Society in London on Friday 11 – Saturday 12 October 2013, with an ice-breaker drinks reception on the evening of Thursday 10th October 2013.

This important two day symposium will unite 300 clinicians and researchers to explore key areas of research into synergism between immunotherapy and standard treatments in oncology and will offer an unparalleled opportunity for the international research and clinical community to come together and explore the opportunities and challenges that exist today in immunotherapy.

Key themes of the symposium:

How chemotherapy alters the immunogenicity of tumour cells

The effects of chemotherapy on immune regulation

The effects of chemotherapy on effector cells of the immune system

Clinical studies exploring the combinations of chemotherapy and immunotherapy

For further information click here